Case Report Sympathetic renal denervation in hypertension with chronic kidney disease: a case report and review of literature
|
|
- Shana Erin Flynn
- 5 years ago
- Views:
Transcription
1 Int J Clin Exp Med 2015;8(9): /ISSN: /IJCEM Case Report Sympathetic renal denervation in hypertension with chronic kidney disease: a case report and review of literature Yingyi Wu 1*, Suyan Duan 2*, Xuxue Qiang 2, Zhangcheng Ning 2, Changying Xing 2, Bo Zhang 2 1 Department of Rheumatology, The Wuxi 4th People s Hospital (The Affiliated Hospital of Jiangnan University), Wuxi , Jiangsu, China; 2 Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Nanjing , Jiangsu, China. * Co-first authors. Received July 7, 2015; Accepted September 6, 2015; Epub September 15, 2015; Published September 30, 2015 Abstract: Resistant hypertension is defined as systolic blood pressure that is higher than 140 mmhg even though they consume three maximally tolerated anti-hypertensive medication class, including diuretics at an appropriate dose [1]. There are many complications of resistant hypertension such as left ventricular hypertrophy, increased incidence of retinal hemorrhage and kidney damages [2]. A novel catheter-based technique for renal denervation (RDN) as a new therapeutic avenue has great promise for the treatment of refractory hypertension. Despite the fast pace of development in RDN therapies, only initial and very limited clinical data are available. Here, we present the effects of RDN on perivascular nerves of the renal arteries in a 62-year-old male patient. And large gaps in knowledge concerning the long-term effects and consequences of RDN still exist, and solid, randomized data are warranted. Keywords: Renal denervation, resistant hypertension, chronic kidney disease, renal sympathetic nervous system Introduction Hypertension is a major global public health concern despite the recent advances and proven benefit of pharmacological therapy. A certain subset of patients have hypertension resistant to maximal medical therapy and appropriate lifestyle measures. Meanwhile, chronic kidney disease (CKD) contributes substantially to the global burden of cardiovascular morbidity and mortality. Even a moderate reduction in GFR is predictive of an increased risk for coronary heart disease [3]. Accordingly, hypertensive patients with reduced GFR are at greater risk for cardiovascular disease than for ESRD. Pharmacological treatment for resistant hypertension is currently available. However, the effectiveness of pharmacological treatment for resistant hypertension is low [4]. New approaches in form of therapeutic intervention like RDN may be needed. We herein report a case of RDN on perivascular nerves of the renal arteries in a 62-year-old male patient, with the literature review to understand it better. Case presentation Here we present a patient with resistant hypertension despite use of five different anti-hypertensive drugs. A 62-year-old male patient (BMI: kg/m 2 ) was admitted to our outpatient clinics with poorly controlled hypertension. With 20-year diabetes and 8-year hypertension history, he got uremia 4 years ago and since then he accepted hemodialysis 3 times a week. He presented with long-standing hypertension that was resistant to pharmacological therapy with five different anti-hypertensive drugs, namely Irbesartan 300 mg/day, Nifedipine GITS 270 mg/day, Metoprolol 50 mg/day, Compound Dihydralazine Sulfate Tablets 9 tablets/day and Nimodipine 180 mg/day. His office blood pressure was / mmhg. Echocardiography showed normal left ventricular systolic function and mild mitral insufficiency. Due to the uncontrolled nature of the resistant hypertension, the patient was eligible for percutaneous renal denervation treatment with approval of the hospital ethical committee. This
2 Figure 1. Liu s office-based measurements of systolic and diastolic blood pressures before RDN, and 4 days, 3 months, and 12 months after RDN. (The statistical analyses were performed using the SPSS 20.0 statistical software package. All results are expressed as the mean ± standard deviation (n=3). One-way analysis of variance (ANOVA) was used to perform comparisons among the different groups, and P<0.05 was considered to be statistically significant. * P<0.05 vs. systolic blood pressure before RDN, Δ P<0.05 vs. diastolic blood pressure before RDN). Table 1. Liu s clinical characteristics in the two times of hospitalization Clinical characteristics 1* 2* Dialysis Three times a week Dry weight (kg) Cardiothoracic ratio 58% 55% Ejection fraction 65.10% 60.70% PTH (pg/ml) Hb (g/l) Albumin (g/l) FBG (mmol/l) BUN (mmol/l) Scr (umol/l) ALP (U/L) HbA1c 8.30% 8.60% Novolin30R 6u/4u 6u/4u *1-the first time of hospitalization is for RDN, 2-the second is 3 months later for parathyroidectomy. PTH, parathyroid hormone; Hb, hemoglobin; FBG, fasting blood glucose; Scr, serum creatinine; ALP, alkaline phosphatase. clinical trial named Renal Sympathetic Denervation in Patients with Chronic Kidney Disease and Resistant Hypertension (RSD- 4CKD) was registered in Clinical Trials. gov as number NCT Under local anesthesia, the femoral artery was accessed in standard technique and angiography was performed to visualize the renal artery (diameter >4 mm, length >20 mm, with no stenosis). RDN was performed with Cordis Catheter system (JNJ Inc., Miami, Florida, USA) and Fentanyl was used to relieve pain. Mean temperature was 45 C and 10 W radiofrequency nerve ablations lasted up to 2 minute at each point, with 8 points on the left and 9 points on the right. Radio-frequency ablation was applied to both renal arteries without apparent procedural complications and no vascular complications were observed. The patient was discharged at the fourth day with 160/90 mmhg at office. The patient was prescribed with irbesartan 150 mg/day, Nifedipine GITS 60 mg/day, and Compound Dihydralazine Sulfate Tablets 6 tablets/day. Ambulatory blood pressure has been monitored regularly which revealed an average systolic and diastolic blood pressure of 140/70 mmhg 12 months later (Figure 1). 3 months after his first hospitalization, he was hospitalized again for parathyroidectomy. We compared clinical characteristics and heart rate variability (HRV) in the two times of hospitalization (Tables 1, 2). Our experience suggests that this technique can be safely performed in elderly patients with severely impaired renal function. Discussion In 2009 the first in-human proof-of-concept study (Symplicity I) evaluated 50 patients with treatment-resistant hypertension [5]. BP reduction with RDN was significant, smaller in the first month after RDN (-14/-10 mmhg), and more pronounced at 6-month and 1-year follow-up (-27/-17 mmhg). In 2010 the second study (Symplicity II) with a sample of 106 patients was randomized but not blinded [6]. BP dropped significantly in the first month in the active RDN group, but BP reduction was much greater at 6 months (-32/-12 mmhg). In 2014 the result of the third study (Symplicity III) which was prospective, single-blind, randomized, and sham-controlled came out [7]. A total of 535 patients underwent randomization. The mean systolic blood pressure at 6 months was ±23.93 mmhg in the denervation group as compared with ±25.94 mmhg in the sham-procedure group (P<0.001 for both com Int J Clin Exp Med 2015;8(9):
3 Table 2. Heart rate variability (HRV) of patient Liu s two hospitalization Heart rate variability (HRV) 1* 2* mean 24-h HR mean NN (ms) SDNN (ms) SDANN (ms) rmssd (ms) pnn50 (ms) 0.40% 0.40% *1-the first time of hospitalization is for RDN, 2-the second is 3 months later for Parathyroidectomy. Mean 24-h HR: mean heart rate over 24-h. mean NN: mean normal-to-normal R-R ntervals. SDNN: standard deviation of the normal-to-normal R-R intervals. SDANN: standard deviation of 5-min average of normal R-R intervals. rms- SD: root-mean square of differences between adjacent normal R-R intervals. pnn 50%: proportion of adjacent R-R intervals differing by >50 ms over 24-h. parisons of the change from baseline). There were no significant differences in safety between the two groups. Sympathetic activity is already elevated in early phases of chronic renal failure, and the magnitude of sympathetic overdrive increases with disease progression [8]. Evidence also suggests that the afferent sensory renal nerves in response to intra-renal injury have an excitatory influence on central sympathetic outflow. Consequently, renal sympathetic efferent and afferent nerves exert a powerful influence on the initiation, development, and maintenance of elevated systemic BP commonly present in patients with renal failure. Afferent signaling derived from the native failing kidneys plays a causal role in renal efferent sympatho excitation and potentiates the adverse effect of chronically increased sympathetic drive. Consequently, interruption of efferent and afferent renal fibers may possibly mitigate or reverse autonomic imbalance and reduce renal sympathetic outflow and arterial BP in CKD. Chronic kidney disease is an important cause and consequence of uncontrolled hypertension. Patients with high blood pressure, especially those who are therapy resistant, are at high risk for renal impairment and other cardiovascular complications [9]. Recent findings [10-12] summarize the clinical experience with catheter-based renal nerve ablation in high-risk patients with moderate to severe renal impairment. The main results of this pilot study are as follows: (1) selective and bilateral sympathetic renal denervation is safe and effective in patients with stage 3-4 CKD; (2) bilateral renal denervation is not associated with acute or short-term deterioration of renal function; and (3) bilateral renal nerve ablation may have beneficial effects beyond improved BP control, including a potential increase in hemoglobin concentration and reductions in proteinuria, BNP levels, and peripheral arterial stiffness index. As reviewed above, no studies covered more than one year. The kidneys are critically injured when massive proteinuria is with malignant hypertension, leading to renal insufficiency. Therefore studies should consider long-term prognosis in patients with resistant hypertension as the end point. Besides, for the patients on dialysis, cardiac function and dry weight which correlate with BP should be into consideration. Many issues still remain unclear despite the concept of RDN has high potential, of paramount importance are (i) proper patient selection based on the knowledge of the pathophysiology, (ii) development of a method/variable that can be used to guide the interventionist during the procedure and (iii) long-term data on safety are necessary. The concept of resistant hypertension as selection criterion will gradually disappear, simply because it does not make sense from a pathophysiological point of view. CKD patients are especially likely to benefit from RDN, possibly over the whole range of CKD [13, 14]. Present day standard therapy in CKD patients includes RAAS inhibitors, which reduce but on average do not normalize sympathetic activity. Also, blood pressure is often not adequately controlled in CKD [15]. The beneficial effect of renal denervation may not only include a reduction in cardiovascular morbidity and mortality, but also a reduction in progression of CKD. Other potential patients groups could be heart failure and obesity/metabolic syndrome/type II diabetes. Given the financial burden to society of the ESRD programs, any reduction of CKD progression could be very cost effective. Conclusion Based on the results of the initial and small clinical experience, catheter-based RDN thera Int J Clin Exp Med 2015;8(9):
4 py has great promise for the treatment of refractory hypertension. Safety and efficacy findings seem to suggest that renal sympathetic denervation could be of therapeutic benefit in this patient population. Despite the fast pace of development in RDN therapies, significant gaps in knowledge still exist, especially with regards to possible nerve or vessel injury and long-term consequences. Obviously, we can only achieve the first step for appropriate orientation in the process of further development of this new therapy, which is really a multidisciplinary task requiring collaboration between the device industry, interventional cardiologists, pathologists, electro-physiologists, endovascular physicians, radiologists and nephrologists. Given the nature of this intervention, nephrologists should be heavily involved. Acknowledgements This work was supported by grants from the National Natural Science Foundation of China ( /H0509, /H0509, to Changying Xing; /H0510, to Bo Zhang), the Natural Science Foundation of Jiangsu (BK , to Bo Zhang; LJ201125, BK , BL , BL , to Changying Xing). Disclosure of conflict of interest None. Address correspondence to: Dr. Bo Zhang, Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing Medical University, 300 Guangzhou Road, Nanjing , China. Tel: ; Fax: ; zhangbo2003@medmail.com.cn References [1] Sarafidis PA, Georgianos P and Bakris GL. Resistant hypertension--its identification and epidemiology. Nat Rev Nephrol 2013; 9: [2] Cuspidi C, Meani S, Fusi V, Valerio C, Sala C and Zanchetti A. Prevalence and correlates of aortic root dilatation in patients with essential hypertension: relationship with cardiac and extracardiac target organ damage. J Hypertens 2006; 24: [3] Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T; ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: [4] Sarafidis PA and Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: [5] Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT and Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: [6] Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE and Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: [7] Bhatt DL, Kandzari DE, O Neill WW, D Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL and Investigators SH. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: [8] Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell Oro R and Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: [9] Ruilope LM and Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J 2011; 32: [10] Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Bohm M, Cremers B, Esler MD and Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23: [11] Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U and Bohm M. Renal hemodynamics and renal function after catheterbased renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: [12] Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D and Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013; 8: Int J Clin Exp Med 2015;8(9):
5 [13] de Jager RL and Blankestijn PJ. Pathophysiology I: the kidney and the sympathetic nervous system. EuroIntervention 2013; 9 Suppl R: R [14] Vink EE, de Jager RL and Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013; 15: [15] van Zuilen AD, Bots ML, Dulger A, van der Tweel I, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ and Wetzels JF. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 2012; 82: Int J Clin Exp Med 2015;8(9):
Renal denervation for treatment of resistant hypertension
Renal denervation for treatment of resistant hypertension Dr U. Nqebelele Division of Nephrology Department of Internal Medicine Charlotte Maxeke Johannesburg Academic Hospital Thomas Willis: 1621-1675
More informationRenal Sympathetic Denervation in Resistant Arterial Hypertension: Long Term and Updated Results
Physiol. Res. 68: 129-133, 2019 doi: 10.33549/physiolres.934008 SHORT COMMUNICATION Renal Sympathetic Denervation in Resistant Arterial Hypertension: Long Term and Updated Results J. H. PEREGRIN 1, J.
More informationCatheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension
Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension Henry Krum, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski, Krzysztof Bartus, Boguslaw Kapelak, Horst
More informationCatheter-Based Renal Denervation (RDN)
Hypertension lecture 3: Catheter-Based Renal Denervation (RDN) Adapted from slides prepared by Dr IOEBRAHIM, UNITAS HOSPITAL and others Hypertension Epidemiology 30% Untreated 35% Treated & Controlled
More informationCatheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension
Catheter-Based Renal Denervation Reduces Total Body and Renal Noradrenaline Spillover and Blood Pressure in Resistant Hypertension Murray Esler, Markus Schlaich, Paul Sobotka, Rob Whitbourn, Jerzy Sadowski,
More informationnoradrenaline spillover and systemic blood pressure in patients with resistant hypertension
Effects of renal sympathetic denervation on noradrenaline spillover and systemic blood pressure in patients with resistant hypertension Markus Schlaich Neurovascular Hypertension & Kidney Disease Laboratory
More informationRISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine
RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston
More informationThe Future of Renal Denervation
The Future of Renal Denervation Ron Waksman, MD, FACC, FSCAI Professor of Medicine, (Cardiology) Georgetown University Director, Cardiovascular Research Advanced Education MedStar Heart Institute, Washington
More informationCATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION
CATHETER-BASED RENAL DENERVATION INCREASES INSULIN SENSITIVITY AND IMPROVES GLUCOSE METABOLISM IN PATIENTS WITH RESISTANT HYPERTENSION F. Mahfoud, Ch. Ukena, B. Cremers, I. Kindermann, M. Kindermann, P.
More informationReal World Experience with Renal Denervation Therapy
JCR 2013 Real World Experience with Renal Denervation Therapy Seung-Hyuk Choi Division of Cardiology Samsung Medical Center Seoul, Korea Hypertension A Major Public Health Burden Astonishing prevalence
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationEffect of renal denervation on glucose metabolism after a 12 month follow-up
Effect of renal denervation on glucose metabolism after a 12 month follow-up Daniel Matous a, Otakar Jiravsky a, Igor Nykl a, Marian Branny a Background. Renal denervation is an invasive endovascular procedure
More informationNurse-sensitive factors in hypertension management
Nurse-sensitive factors in hypertension management Hypertension treatment State of the Art Copper Hall 14:45-15:04 02/04/2011 Philippe van de Borne, MD, PhD Department of cardiology ULB-Erasme Hospital
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationDevice-based Therapies for Resistant Hypertension: Current Status
Mohsin Wali, C Venkata S Ram Therapeutic 10.5005/jp-journals-10043-0070 Device-based Therapies for Resistant Hypertension: Current Status 1 Mohsin Wali, 2 C Venkata S Ram ABSTRACT Resistant hypertension
More informationRenal Artery Denervation New Concepts in Hypertension Treatment
Renal Artery Denervation New Concepts in Hypertension Treatment Istanbul Course of Interventional Cardiology J. Weil Medizinische Klinik II Kardiologie, Angiologie und internistische Intensivmedizin Universitätsklinikum,
More informationClinical Policy Title: Renal denervation
Clinical Policy Title: Renal denervation Clinical Policy Number: 09.03.04 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: January 11, 2018 Next Review Date:
More informationChristian Daugaard Peters, MD, PhD Department of Renal Medicine Aarhus University Hospital, Denmark Disclosures: None
The effect of renal denervation on central blood pressure and arterial stiffness in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationRadiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension Policy Number: 7.01.136 Last Review: 5/2018 Origination: 11/2015 Next Review: 11/2018 Policy Blue Cross
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationRenal denervation: Current evidence and remaining uncertainties
Renal denervation: Current evidence and remaining uncertainties Michel Azizi Georges Pompidou European Hospital Hypertension Unit ESH excellence Center Paris Descartes University Clinical Investigation
More informationFeasibility of catheter ablation renal denervation in mild resistant hypertension
Received: 16 August 2016 Revised: 8 November 2016 Accepted: 11 November 2016 DOI: 10.1111/jch.12988 ORIGINAL PAPER Feasibility of catheter ablation renal denervation in mild resistant hypertension Shaojie
More informationRadiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1
Radiofrequency Energy Provides Safe & Durable Blood Pressure Reduction: Complete 3 Year Results from Symplicity HTN-1 Henry Krum MBBS PhD FRACP FESC for the Symplicity I Investigators CCRE Therapeutics,
More informationResearch Article. Abstract. Received: 22 August 2017; Accepted: 05 September 2017; Published: 07 September 2017
Research Article Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Residual Pulmonary Hypertension after Pulmonary Thromboembolism and Surgical Thrombectomy B. Rudenko 1*,
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationMP Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Medical Policy Radiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension BCBSA Ref. Policy: 7.01.136 Last Review: 09/19/2018 Effective Date: 09/19/2018 Section:
More informationMINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings
NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION
More informationThe Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension
The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension Michael Böhm, MD on behalf of the GSR Investigators March 30,
More informationRenal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction?
Renal Sympathetic Denervation Beyond Hypertension: Therapy for Arrhythmias and for Autonomic Nervous System Dysfunction? Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia
More informationRadiofrequency Ablation of the Renal Sympathetic Nerves as a Treatment for Resistant Hypertension
Last Review Status/Date: December 2014 Page: 1 of 18 Nerves as a Treatment for Resistant Hypertension Description Radiofrequency ablation (RFA) of the renal sympathetic nerves is a non-pharmacologic treatment
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationA Controlled Trial of Renal Denervation for Resistant Hypertension
original article A Controlled Trial of Renal Denervation for Resistant Hypertension Deepak L. Bhatt, M.D., M.P.H., David E. Kandzari, M.D., William W. O Neill, M.D., Ralph D Agostino, Ph.D., John M. Flack,
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationWhat We've Learned from Simplicity HTN-1,2, and Registries
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 What We've Learned from Simplicity HTN-1,2, and Registries Horst Sievert, Ann-Kathrin Ziegler, Benjamin Kaltenbach, Ilona Hofmann, Undine Pittl
More informationTHE BLOOD PRESSURE PROCEDURE
THE BLOOD PRESSURE PROCEDURE An innovative procedure that could help lower your blood pressure. THIS BOOKLET IS DESIGNED TO HELP YOU LEARN MORE ABOUT THE BLOOD PRESSURE PROCEDURE CALLED RDN CONTENTS 4
More informationRenal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;
Renal Denervation Henry Krum MBBS PhD FRACP Centre of Cardiovascular Research & Education in Therapeutics, Monash University/Alfred Hospital; Alfred Heart Centre, The Alfred Hospital, Melbourne Australia
More informationByeong-Keuk Kim, MD, PhD. Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea
Byeong-Keuk Kim, MD, PhD Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul, Korea BP change (mmhg) from Baseline to 6 Months (mmhg) Catheter-based renal
More informationUpdate on renal denervation: Latest data
LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research
More informationHypertension: the Heart Vs the Kidney. George Moturi Physician/Nephrologist Aga Khan Hospital Nairobi
Hypertension: the Heart Vs the Kidney George Moturi Physician/Nephrologist Aga Khan Hospital Nairobi 24 th Feb, 2017 Travel facilitation from Novartis Disclaimer Systolic blood pressure (SBP) of at least
More informationPreliminary experience with Ardian Symplicity system in renal denervation for the treatment of arterial hypertension resistant to medical therapy
Preliminary experience with Ardian Symplicity system in renal denervation for the treatment of arterial hypertension resistant to medical therapy Poster No.: C-0768 Congress: ECR 2011 Type: Scientific
More informationImpact of Renal Denervation on 24-hour Ambulatory Blood Pressure: Results from SYMPLICITY HTN-3
Accepted Manuscript Impact of Renal Denervation on 24-hour Ambulatory Blood Pressure: Results from SYMPLICITY HTN-3 George L. Bakris, MD Raymond R. Townsend, MD Minglei Liu, PhD Sidney A. Cohen, MD, PhD
More informationThe American College of Cardiology (ACC) and American
Could it be PARADISE Found or is SYMPLICITY the Answer to the Treatment of Hypertension: The Resurrection of Renal Denervation to Treat Hypertension New Studies and Newer Options Richard R Heuser, MD and
More informationEnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension
EnligHTN I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou, MD 1 Prof. Stephen Worthley, MD 2 Costas
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationManagement of Resistant Hypertension in Diabetes
Management of Resistant Hypertension in Diabetes Soon Hee Lee, M.D., Ph.D. Divisoin of Endocrinology & Metabolism, Department of Internal Medicine, Busan Paik Hospital, College of Medicine, Inje University,
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationRenal Denervation: The Case for Cardiology
Renal Denervation: The Case for Cardiology John C. Gurley, MD University of Kentucky Presenter Disclosure Information John C Gurley, MD Renal Denervation: The Case for Cardiology FINANCIAL DISCLOSURE:
More informationHYPERTENSION GUIDELINES: BEING NORMAL JUST GOT HARDER
HYPERTENSION GUIDELINES: BEING NORMAL JUST GOT HARDER Sarah E Schroeder ACNP-BC, MSN RN, AACC Bryan Heart Fall Nursing Conference Lincoln, Nebraska USA October 13, 2018 DISCLOSURES None OBJECTIVES Hypertension
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBaroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension
Baroreflex Activation Therapy: Integrated Autonomic Neuromodulation for Heart Failure and Hypertension Robert S. Kieval, VMD, PhD Founder & Chief Technology Officer, CVRx, Inc. Financial Disclosure I,
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationTranscatheter Perivascular Alcohol- Mediated Renal Denervation
Transcatheter Perivascular Alcohol- Mediated Renal Denervation Wojtek Wojakowski, MD, PhD Medical University of Silesia American Heart of Poland Katowice, Poland I, Wojciech Wojakowski DO NOT have a financial
More informationA New Treatment for Chronic Kidney Disease: Denervation in the Collecting System with the Verve Medical Device
A New Treatment for Chronic Kidney Disease: Denervation in the Collecting System with the Verve Medical Device RICHARD R. HEUSER, MD, FACC, FACP, FESC, FSCAI Chief of Cardiology, St. Luke s Medical Center
More informationDepartment of Nephrology
OUTCOMES DIVISION OF MEDICINE Department of Nephrology About Cleveland Clinic Florida Cleveland Clinic Florida s medical staff are dedicated physicians who have joined the clinic as salaried doctors to
More informationSPYRAL HTN ON MED. Disclosure
Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial Dr. David E. Kandzari Piedmont Heart Institute,
More informationStephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.
Six Month Results of First-in-Human Sympathetic Renal Artery Denervation Using a Next Generation Multi-Electrode Renal Artery Denervation System in Patients with Drug-Resistant Hypertension Stephen G.
More informationWith an unrestricted educational grant from. The Interventional Treatment of Resistant Hypertension
With an unrestricted educational grant from The Interventional Treatment of Resistant Hypertension Felix Mahfoud Interventional Cardiology University Hospital Homburg/Saar Germany Dr. Mahfoud graduated
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationPerspectives Article: American Journal of Physiology - Renal Physiology
Perspectives Article: American Journal of Physiology - Renal Physiology What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivity Markus
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationThere is extensive evidence that renal afferent and efferent. Renal Denervation
Reinnervation of Renal Afferent and Efferent Nerves at 5.5 and 11 Months After Catheter-Based Radiofrequency Renal Denervation In Sheep Lindsea C. Booth,* Erika E. Nishi,* Song T. Yao, Rohit Ramchandra,
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationTreating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 22 June 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationOriginal Article Influence of renal sympathetic denervation on the cardiac function of dogs with heart failure
Int J Clin Exp Med 2016;9(2):4324-4331 www.ijcem.com /ISSN:1940-5901/IJCEM0014662 Original Article Influence of renal sympathetic denervation on the cardiac function of dogs with heart failure Damin Huang
More information만성콩팥병환자에서의혈압관리 분당서울대병원신장내과 안신영
만성콩팥병환자에서의혈압관리 분당서울대병원신장내과 안신영 Contents Introduction Lifestyle and Pharmacological Tx CKD ND ptswithout diabetes CKD ND ptswith diabetes In elderly ptswith CKD ND 2013 대한고혈압학회진료지침 JNC 8th Introduction
More informationDisclosures for Dr. Bhatt
Renal Denervation Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Executive Director of Interventional Cardiovascular Programs, BWH Heart & Vascular Center Professor of Medicine, Harvard Medical School
More informationBackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure. Daniel Burkhoff MD PhD
BackBeat Cardiac Neuromodulation Therapy (CNT) for Immediate, Substantial and Sustained Lowering of Blood Pressure Daniel Burkhoff MD PhD Director Heart Failure, Hemodynamics and Mechanical Support Research
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationChristopher Valentine, MD
Resistant Hypertension Christopher Valentine, MD Program Director, Nephrology Fellowship Program Department of Internal Medicine Division of Nephrology The Ohio State University Wexner Medical Center Disclosures
More informationDevices and Long-Term Outcomes of Renal Denervation for Hypertension
18th ANGIOPLASTY SUMMIT-TCTAP 2013 Seoul, Korea, April 23-26, 2013 Devices and Long-Term Outcomes of Renal Denervation for Hypertension Horst Sievert, Ilona Hofmann, Laura Vaskelyte, Stefan Bertog, Simon
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationObstructive sleep apnea (OSA) is considered an etiologic
Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea Adam Witkowski, Aleksander Prejbisz, Elżbieta
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationΣύγτρονη θεραπεία της ανθεκτικής σπέρτασης
Σύγτρονη θεραπεία της ανθεκτικής σπέρτασης Κώζηας Τζιούθης Α Παν/κή Καρ/κή Κλινική Ιπποκράηειο Γ.Ν.Α. Resistant or Refractory to treatment Hypertension Office BP>140/90 or 130/80 mm Hg in patients with
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationRenal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial
Renal Sympathetic Denervation for Treatment of Resistant Hypertension: 18-Month Results from the Symplicity HTN-2 Randomized Controlled Trial Prof Murray Esler Baker IDI Heart and Diabetes Institute, Melbourne
More informationRenal Denervation for Resistant Hypertension
Renal Denervation for Resistant Hypertension James W. Choi MD FACC FSCAI Cardiology Consultants of Texas Director Interventional Cardiology Fellowship Baylor University Medical Center Baylor Heart & Vascular
More informationPCI for Renal Artery stenosis
PCI for Renal Artery stenosis Why should we treat Renal Artery Stenosis? Natural History of RAS RAS is progressive disease Study Follow-up (months) Pts Progression N (%) Total occlusion Wollenweber Meaney
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationUniversity of Groningen. Acute kidney injury after cardiac surgery Loef, Berthus Gerard
University of Groningen Acute kidney injury after cardiac surgery Loef, Berthus Gerard IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationA Three-Arm Randomized Trial of Different Renal Denervation Devices and. Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN)
A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN) Running Title: Fengler et al.; Comparison of Renal Denervation
More information622 KARIO K et al. Safety and Efficacy of Renal Denervation at 3 Years
622 KARIO K et al. Circulation Journal ORIGINAL ARTICLE Circ J 2019; 83: 622 629 doi: 10.1253/circj.CJ-18-1018 Hypertension and Circulatory Control Sufficient and Persistent Blood Pressure Reduction in
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationAgenda. Management of Accelerated Hypertension (Updated in 2017) Salwa Roshdy Prof. of Cardiology Assiut University CardioEgypt 23/2/2017 2/27/2017
Management of Accelerated Hypertension (Updated in 2017) By Salwa Roshdy Prof. of Cardiology Assiut University CardioEgypt 23/2/2017 Agenda Definition of Accelerated HTN Pathophysiology & Etiology Prognosis
More informationDiastology State of The Art Assessment
Diastology State of The Art Assessment Dr. Mohammad AlGhamdi Assistant professor, KSAU-HS Consultant Cardiologist King AbdulAziz Cardiac Center Ministry of National Guard Health Affairs Diagnostic Clinical
More informationTreating Hypertension With a Catheter..Wait What? COI 5/3/2013. Worldwide Prevalence of Hypertension Is Increasing
Treating Hypertension With a Catheter..Wait What? David P. Lee, M.D. 4 May 2013 Stanford University COI Medtronic: Research Grant, Consultant Boston Scientific: Research Grant, MAB Worldwide Prevalence
More informationRenal sympathetic denervation as a potential treatment for hypertension
Renal sympathetic denervation as a potential treatment for hypertension (Why we must keep going) Dr Andrew SP Sharp Consultant Cardiologist and Honorary Senior Lecturer Royal Devon and Exeter Hospital
More information